Clinical Trial Update: A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) [Phase 4]

View source ↗

Summary

A 24-week Phase 4 trial comparing umeclidinium/vilanterol (UMEC/VI), umeclidinium (UMEC) alone, and salmeterol in COPD patients has completed with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Salmeterol (salmeterol)
• Umeclidinium (umeclidinium)
• Umeclidinium/Vilanterol (umeclidinium/vilanterol)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 4 | Status: COMPLETED | Results posted: 2019-07-15